DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced today that it has signed a non-exclusive license agreement with Amgen for access to DSM's proprietary XD high cell density process patents.
XD technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes. For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.
